-
2
-
-
77249120064
-
Treatment of multiple myeloma: A comprehensive review
-
Kyle RA, Rajkumar SV,. Treatment of multiple myeloma: a comprehensive review. Clin Lymphoma Myeloma. 2009; 9: 278-288.
-
(2009)
Clin Lymphoma Myeloma.
, vol.9
, pp. 278-288
-
-
Kyle, R.A.1
Rajkumar, S.V.2
-
3
-
-
8944220233
-
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome
-
Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med. 1996; 335: 91-97.
-
(1996)
N Engl J Med.
, vol.335
, pp. 91-97
-
-
Attal, M.1
Harousseau, J.L.2
Stoppa, A.M.3
-
4
-
-
0037739753
-
High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma
-
Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003; 348: 1875-1883.
-
(2003)
N Engl J Med.
, vol.348
, pp. 1875-1883
-
-
Child, J.A.1
Morgan, G.J.2
Davies, F.E.3
-
5
-
-
79953718494
-
Phase II trial of high-dose topotecan, melphalan and CY with autologous stem cell support for multiple myeloma
-
Kazmi SM, Saliba RM, Donato M, et al. Phase II trial of high-dose topotecan, melphalan and CY with autologous stem cell support for multiple myeloma. Bone Marrow Transplant. 2011; 46: 510-515.
-
(2011)
Bone Marrow Transplant.
, vol.46
, pp. 510-515
-
-
Kazmi, S.M.1
Saliba, R.M.2
Donato, M.3
-
6
-
-
2642517876
-
Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma
-
Anagnostopoulos A, Aleman A, Ayers G, et al. Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma. Cancer. 2004; 100: 2607-2612.
-
(2004)
Cancer.
, vol.100
, pp. 2607-2612
-
-
Anagnostopoulos, A.1
Aleman, A.2
Ayers, G.3
-
7
-
-
0036464598
-
2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: Final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial
-
2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood. 2002; 99: 731-735.
-
(2002)
Blood.
, vol.99
, pp. 731-735
-
-
Moreau, P.1
Facon, T.2
Attal, M.3
-
8
-
-
34247177131
-
Results of a retrospective single institution analysis of targeted skeletal radiotherapy with Holmium-DOTMP as conditioning regimen for autologous stem cell transplant for patients with multiple myeloma. Impact on transplant outcomes
-
Christoforidou AV, Saliba RM, Williams P, et al. Results of a retrospective single institution analysis of targeted skeletal radiotherapy with Holmium-DOTMP as conditioning regimen for autologous stem cell transplant for patients with multiple myeloma. Impact on transplant outcomes. Biol Blood Marrow Transplant. 2007; 13: 543-549.
-
(2007)
Biol Blood Marrow Transplant.
, vol.13
, pp. 543-549
-
-
Christoforidou, A.V.1
Saliba, R.M.2
Williams, P.3
-
9
-
-
0037973279
-
A phase 2 study of bortezomib in relapsed, refractory myeloma
-
Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003; 348: 2609-2617.
-
(2003)
N Engl J Med.
, vol.348
, pp. 2609-2617
-
-
Richardson, P.G.1
Barlogie, B.2
Berenson, J.3
-
10
-
-
20444433230
-
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma
-
Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005; 352: 2487-2498.
-
(2005)
N Engl J Med.
, vol.352
, pp. 2487-2498
-
-
Richardson, P.G.1
Sonneveld, P.2
Schuster, M.W.3
-
11
-
-
73349115580
-
Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma
-
Richardson PG, Weller E, Jagannath S, et al. Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma. J Clin Oncol. 2009; 27: 5713-5719.
-
(2009)
J Clin Oncol.
, vol.27
, pp. 5713-5719
-
-
Richardson, P.G.1
Weller, E.2
Jagannath, S.3
-
12
-
-
0037342894
-
The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents
-
Ma MH, Yang HH, Parker K, et al. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res. 2003; 9: 1136-1144.
-
(2003)
Clin Cancer Res.
, vol.9
, pp. 1136-1144
-
-
Ma, M.H.1
Yang, H.H.2
Parker, K.3
-
13
-
-
0037443551
-
The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: Therapeutic applications
-
Mitsiades N, Mitsiades CS, Richardson PG, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood. 2003; 101: 2377-2380.
-
(2003)
Blood.
, vol.101
, pp. 2377-2380
-
-
Mitsiades, N.1
Mitsiades, C.S.2
Richardson, P.G.3
-
14
-
-
50449086728
-
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma
-
San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008; 359: 906-917.
-
(2008)
N Engl J Med.
, vol.359
, pp. 906-917
-
-
San Miguel, J.F.1
Schlag, R.2
Khuageva, N.K.3
-
15
-
-
74949119502
-
Intergroupe Francophone du Myelome (IFM). Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: A phase 2 study of the Intergroupe Francophone du Myelome (IFM)
-
.
-
Roussel M, Moreau P, Huynh A, et al. Intergroupe Francophone du Myelome (IFM). Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM). Blood. 2010; 15: 32-37.
-
(2010)
Blood.
, vol.15
, pp. 32-37
-
-
Roussel, M.1
Moreau, P.2
Huynh, A.3
-
16
-
-
56549083786
-
Arsenic trioxide with ascorbic acid and high-dose melphalan: Results of a phase II randomized trial
-
Qazilbash MH, Saliba RM, Nieto Y, et al. Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trial. Biol Blood Marrow Transplant. 2008; 14: 1401-1407.
-
(2008)
Biol Blood Marrow Transplant.
, vol.14
, pp. 1401-1407
-
-
Qazilbash, M.H.1
Saliba, R.M.2
Nieto, Y.3
-
17
-
-
84988241358
-
International uniform response criteria for multiple myeloma
-
Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006; 20: 1467-1473.
-
(2006)
Leukemia.
, vol.20
, pp. 1467-1473
-
-
Durie, B.G.1
Harousseau, J.L.2
Miguel, J.S.3
-
18
-
-
77649151227
-
In the age of novel therapies, what defines high-risk multiple myeloma?
-
Badros AZ,. In the age of novel therapies, what defines high-risk multiple myeloma? J Natl Compr Canc Netw. 2010; 8 (suppl 1): S28-S34.
-
(2010)
J Natl Compr Canc Netw.
, vol.8
, Issue.SUPPL. 1
-
-
Badros, A.Z.1
-
20
-
-
0002386913
-
On the interpretation of x2 from contingency tables, and the calculation of P
-
Fischer R,. On the interpretation of x2 from contingency tables, and the calculation of P. J R Stat Soc. 1922; 85: 87-94.
-
(1922)
J R Stat Soc.
, vol.85
, pp. 87-94
-
-
Fischer, R.1
-
22
-
-
33845382806
-
Non-parametric estimation from incomplete observation
-
Kaplan EL, Meier P,. Non-parametric estimation from incomplete observation. J Am Stat Assoc. 1958; 53: 457-481.
-
(1958)
J Am Stat Assoc.
, vol.53
, pp. 457-481
-
-
Kaplan, E.L.1
Meier, P.2
-
23
-
-
0013886333
-
Evaluation of survival data and 2 new rank order statistics arising in its consideration
-
Mantel N,. Evaluation of survival data and 2 new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966; 50: 163-170.
-
(1966)
Cancer Chemother Rep.
, vol.50
, pp. 163-170
-
-
Mantel, N.1
-
25
-
-
0000120766
-
Estimating the dimension of a model
-
Schwarz GE,. Estimating the dimension of a model. Ann Stat. 1978; 6: 461-464.
-
(1978)
Ann Stat.
, vol.6
, pp. 461-464
-
-
Schwarz, G.E.1
-
26
-
-
79956039754
-
Consensus recommendations for risk stratification in multiple myeloma: Report of the International Myeloma Workshop Consensus Panel 2
-
Munshi NC, Anderson KC, Bergsagel PL, et al. Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood. 2011; 117: 4696-4700.
-
(2011)
Blood.
, vol.117
, pp. 4696-4700
-
-
Munshi, N.C.1
Anderson, K.C.2
Bergsagel, P.L.3
-
28
-
-
0029971972
-
Hyper-CVAD for VAD-resistant multiple myeloma
-
Dimopoulos MA, Weber D, Kantarjian H, Delasalle KB, Alexanian R,. Hyper-CVAD for VAD-resistant multiple myeloma. Am J Hematol. 1996; 52: 77-81.
-
(1996)
Am J Hematol.
, vol.52
, pp. 77-81
-
-
Dimopoulos, M.A.1
Weber, D.2
Kantarjian, H.3
Delasalle, K.B.4
Alexanian, R.5
-
29
-
-
77958065790
-
A phase I/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: A dose- and schedule-finding study
-
Lonial S, Kaufman J, Tighiouart M, et al. A phase I/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: a dose- and schedule-finding study. Clin Cancer Res. 2010; 16: 5079-5086.
-
(2010)
Clin Cancer Res.
, vol.16
, pp. 5079-5086
-
-
Lonial, S.1
Kaufman, J.2
Tighiouart, M.3
-
30
-
-
33644510445
-
Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma
-
Qazilbash MH, Saliba R, De Lima M, et al. Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma. Cancer. 2006; 106: 1084-1089.
-
(2006)
Cancer.
, vol.106
, pp. 1084-1089
-
-
Qazilbash, M.H.1
Saliba, R.2
De Lima, M.3
-
31
-
-
70450189443
-
Commentary on Perrone, et al. "vitamin C: Not for breakfast anymore. if you have myeloma."
-
Harvey RD, Nettles J, Wang B, Sun SY, Lonial S,. Commentary on Perrone, et al. "vitamin C: not for breakfast anymore. if you have myeloma." Leukemia. 2009; 23: 1939-1940.
-
(2009)
Leukemia.
, vol.23
, pp. 1939-1940
-
-
Harvey, R.D.1
Nettles, J.2
Wang, B.3
Sun, S.Y.4
Lonial, S.5
-
32
-
-
70349303770
-
Ascorbic acid inhibits antitumor activity of bortezomib in vivo
-
Perrone G, Hideshima T, Ikeda H, et al. Ascorbic acid inhibits antitumor activity of bortezomib in vivo. Leukemia. 2009; 23: 1679-1686.
-
(2009)
Leukemia.
, vol.23
, pp. 1679-1686
-
-
Perrone, G.1
Hideshima, T.2
Ikeda, H.3
|